Skip to content
  • Home
  • About Us
  • Shop
    • Chinese innovative drug
    • Tablets
    • Capsules
    • Injection
    • oral solution
    • Cream/Gel/Ointment
    • ophthalmic preparations
    • Nasal preparations
    • Inhalation preparation
    • Implant
    • Chinese Medicine
  • Blog
  • Contact Us
Xpharma China
Shopping cart$0.00 0
Login
  • Home
  • About Us
  • Shop
    • Chinese innovative drug
    • Tablets
    • Capsules
    • Injection
    • oral solution
    • Cream/Gel/Ointment
    • ophthalmic preparations
    • Nasal preparations
    • Inhalation preparation
    • Implant
    • Chinese Medicine
  • Blog
  • Contact Us
Xpharma China
Remegen
  • Approved News

Remegen :Telitacicept receives approval for dual indications.

  • Approved News

Teva :AJOVY®Fremanezumab-vfrmapproved for marketing in China.

Roche
  • Approved News

Roche :bexobrutideg has been in-licensed for development

Zenshine
  • Approved News

Zenshine :Jikeshu®Sebaloxavir Marboxil Tablets approved for marketing in China.

Amaryl (Glimepiride Tablets)
  • Drug news

How much does Amaryl (Glimepiride Tablets) Cost& price without insurance in China?

Yunzhi (Colchicine Tablets)
  • Drug news

How much does Yunzhi (Colchicine Tablets) Cost& price without insurance in China?

Zhuoqing (Spectinomycin Hydrochloride for Injection)
  • Drug news

How much does Zhuoqing (Spectinomycin Hydrochloride for Injection) Cost& price without insurance in China?

Hengrui
  • Approved News

Hengrui :Aiweida®Trastuzumab RezetecanGranted Priority Review

Hengrui
  • Approved News

Hengrui Medicine, Innovent Biologics, and Haisco Pharmaceutical: Bundling pipelines in out-licensing deals and Co-Co partnerships with global pharma giants, reshaping industry norms.

Jascayd (Nerandomilast Tablets)
  • Drug news

How much does Jascayd (Nerandomilast Tablets) Cost& price without insurance in China?

everest medicines
  • Approved News

Everest Medicines:LNZ100 (1.44% aceclidine ophthalmic solution, US brand name VIZZ) — Everest Medicines has acquired the exclusive rights to develop, manufacture, and commercialize this product in Greater China, including mainland China, Hong Kong SAR, Macao SAR, and Taiwan region.

  • Approved News

CSPC:SYS6063 Dual-Target CAR-T Therapy Receives Clinical Trial Approval

Prev
1 … 4 5 6 7 8 9 10 … 22
Next
Contact us

WeChat: +86 139 2425 9988
WhatsApp : +852 9100 6363
Email: info@xpharma.com.cn

Rm F2-48, 6/F, No. 47 Guomao Road, Hainan, China

Useful Links
  • Medicines
  • Chinese innovative drug
  • Medicines Approved News
  • Drug Development News
  • Drug News
  • Privacy Policy
Email Newsletter

Subscribe to our newsletter and get 10% off your first purchase

Copyright © {2026} -Xpharma China